-58%

est. 2Y upside i

HealthcareSeries A

Rank

#1122

Sector

Biotechnology / Healthcare Technology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Cellino operates in a promising, high-growth regenerative medicine market with a strong proprietary technology moat.

Last updated: March 10, 2026

Bull (25%)+300%

Cellino's Nebula platform achieves widespread adoption as the industry standard for iPSC biomanufacturing, securing multiple major partnerships for diverse therapeutic applications. Revenue scales significantly to over $100M by 2028, justifying a $600M+ valuation (4x current), leading to a strong acquisition or IPO where common shareholders realize substantial returns above the $125M preference stack.

Base (40%)+75%

Cellino continues to grow steadily, expanding its iPSC foundry services and securing additional partnerships, but faces ongoing regulatory complexities and high capital requirements. Revenue reaches ~$50M by 2028, leading to an exit valuation of approximately $262.5M (1.75x current). While this provides a meaningful return for common shareholders above the $125M preference stack, it is not a breakout success.

Bear (35%)-70%

Regulatory hurdles prove more challenging than anticipated, or larger incumbents develop competing automated iPSC solutions, eroding Cellino's market position. High capital burn necessitates a down round or a low-valuation acquisition (e.g., $45M, -70% from current), resulting in common shareholders receiving little to no return due to the $125M liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

75%

Investors hold $125M in liquidation preferences ahead of common stock on a $150M valuation.

Dilution Risk

high

As a Series A company with very high capital intensity, additional funding rounds are highly likely, leading to further dilution for common shareholders.

Secondary Liquidity

limited

Cellino stock is a private security, requiring accredited investor status and trading through direct company engagement or secondary marketplaces like Nasdaq Private Market.

Questions to Ask at the Interview

Strategic questions based on Cellinobio's data — designed to show you've done your homework.

  • 1

    “Given the high capital intensity of developing and scaling iPSC biomanufacturing, how does Cellino plan to manage its burn rate and secure future funding rounds without excessive dilution, especially considering the current preference stack?”

  • 2

    “With the launch of the Nebula-Powered iPSC Foundry and partnerships like Karis Bio, what are the key milestones and metrics the company is focused on to demonstrate market penetration and accelerate revenue growth beyond the current ~$25.1M over the next 24 months?”

  • 3

    “Considering Cellino's Series A stage and the significant liquidation preferences, what is the company's anticipated timeline and strategy for a liquidity event (e.g., IPO or acquisition) that would provide meaningful returns for common stock equity holders?”

Community

Valuation Sentiment

Our model estimates -58% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.